• Europe
    • Menu

    Zoetis

    Local communities support future agriculture leaders

    Company News
    calendar icon 21 February 2024
    clock icon 2 minute read

    Zoetis introduces Mhp Guardian – a personalized Mhp management program

    Disease Managing disease Non-notifiable diseases
    calendar icon 1 February 2023
    clock icon 3 minute read
    A step-by-step approach tailored to your goals

    PCV2 Sow Vaccination Recommendations

    Disease Managing disease Treatments and prevention
    calendar icon 30 January 2023
    clock icon 2 minute read
    Recommendations for vaccinating gilts, sows and piglets.

    Impact of MDA on immune responses to PCV2 vaccination

    Disease Treatments and prevention Vaccination
    calendar icon 30 January 2023
    clock icon 2 minute read
    MDA can inhibit serological responses to PCV2 vaccination

    The secret to producing PCV2-negative piglets...

    Disease
    calendar icon 30 January 2023
    clock icon 3 minute read
    PCV2-negative sows.

    Our Partners

    Targan Lallemand Lanxess Hamlet Protein Thermo Fisher Scientific Axcentive

    June 2020 - October 2022

    Research Summary: IMPROVEST® (gonadotropin releasing factor analog-diptheria toxoid conjugate) 0.2 mg/mL administration timing impacts performance outcomes in gilts

    Herd management Production Management Feed and nutrition
    calendar icon 31 October 2022
    clock icon 4 minute read

    A new solution helps improve herd uniformity, closes the Gilt Gap

    Herd management Gilt management
    calendar icon 12 October 2022
    clock icon 7 minute read
    Zoetis launches IMPROVEST® (gonadotropin releasing factor analog-diphtheria toxoid conjugate) 0.2 mg/mL for estrus suppression in market gilts

    Vaccine trial data versus lineage: What’s the best way to predict PRRS vaccine performance?

    Disease Notifiable diseases PRRS
    calendar icon 29 June 2020
    clock icon 5 minute read

    Zoetis statement on CVMP opinion relative to Suvaxyn PRRS MLV

    Disease
    calendar icon 23 June 2020
    clock icon 2 minute read
    No product-specific concern identified for Suvaxyn PRRS MLV and benefit/risk balance for the product remains favourable.
    11 posts 1 2 — 2 <

    Our Partners

    Targan Lallemand Lanxess Hamlet Protein Thermo Fisher Scientific Axcentive
    No Advert Set
    © 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.
  • Our Sites